Canaccord, Wedbush initiate bullish coverage on Enzymotec

Canaccord starts recently public Enzymotec (ENZY +1%) at Buy.

Analyst Scott Van Winkle says the company "is well positioned to drive sustained growth in the highly attractive nutrition market, translating into strong sales, margin, and earnings momentum."

Price target is $24, representing a 35% upside from Monday's close.

Also picking up coverage is Wedbush, where analyst Rommel Dionisio starts the shares at Outperform with a $21 price target. "With its proprietary technology in lipids and expanding global distribution platform, ENZY will continue to gain market share within three fast-growing industry segments of nutritional foods and supplements: krill oil; infant nutrition; and medical foods,"  Dionisio says.

Wedbush note is here

Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs